排序方式: 共有88条查询结果,搜索用时 46 毫秒
1.
Rupture of the distal biceps tendon: evaluation with MR imaging 总被引:2,自引:0,他引:2
2.
3.
Falchook GS Long GV Kurzrock R Kim KB Arkenau TH Brown MP Hamid O Infante JR Millward M Pavlick AC O'Day SJ Blackman SC Curtis CM Lebowitz P Ma B Ouellet D Kefford RF 《Lancet》2012,379(9829):1893-1901
4.
5.
6.
Purpose: We evaluated safety and activity of talactoferrin, a novel immunomodulatory protein in a phase IB trial of patients with
refractory solid tumors. Methods: Thirty-six patients with metastatic cancer who had progressed on, or were ineligible for, standard chemotherapy received
single-agent oral talactoferrin. Following dose-escalation, with no DLTs , patients were randomized to 4.5 or 9 g/day talactoferrin.
Results: Talactoferrin was well tolerated with apparent anti-cancer activity, particularly in NSCLC and RCC. One patient had a PR
(RECIST) and 17 patients (47%) had stable disease (50% disease control rate). Median PFS in the twelve NSCLC and seven RCC
patients was 4.2 and 7.3 months, respectively. There was no apparent difference in anti-tumor activity or adverse events between
talactoferrin doses. Conclusions: Oral talactoferrin was well tolerated. Although evaluated in a small number of patients, talactoferrin appeared to have
anti-cancer activity, particularly in NSCLC and RCC and should be evaluated further. 相似文献
7.
El-Osta H Hong D Wheler J Fu S Naing A Falchook G Hicks M Wen S Tsimberidou AM Kurzrock R 《The oncologist》2011,16(9):1292-1298
Background.
Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies.Methods.
We reviewed the medical records of 155 consecutive patients who had one or more research biopsies as part of a phase I trial from September 2004 to October 2009.Results.
Of 281 research biopsies performed, 118 were paired before and after treatment biopsies (total = 236 biopsies). The most common sites of biopsy were superficial lymph node (19.9%), followed by liver (16.4%), and then soft tissue (15.7%). Ultrasound-guided biopsies were the most frequent type (53.7%). Among 142 patients who consented for mandatory biopsy, 86.6% had the biopsy performed, compared with 4.4% of 911 patients offered a biopsy on an optional basis (p < .0001). Biopsy was obtained most frequently on industry-sponsored trials; lack of funding on nonindustry trials was the most common reason that biopsies were not obtained. Of 281 single biopsies, only 4 (1.4%) had complications: pneumothorax requiring chest tube placement (n = 2), infection requiring admission (n = 1), and arrhythmia with hypotension (n = 1). All but one biopsy was successful in obtaining tissue. No deaths were attributable to biopsy.Conclusions.
Our experience demonstrates that research biopsies in early phase clinical trials are safe (1.4% risk of serious complications), and a higher percentage of patients underwent mandatory biopsies (86.6%) compared with that of the patients with optional biopsies (4.4%). 相似文献8.
9.
10.
Filip Janku Philipp Angenendt Apostolia M. Tsimberidou Siqing Fu Aung Naing Gerald S. Falchook David S. Hong Veronica R. Holley Goran Cabrilo Jennifer J. Wheler Sarina A. Piha-Paul Ralph G. Zinner Agop Y. Bedikian Michael J. Overman Bryan K. Kee Kevin B. Kim E. Scott Kopetz Rajyalakshmi Luthra Frank Diehl Funda Meric-Bernstam Razelle Kurzrock 《Oncotarget》2015,6(27):24581